Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra® (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Abbott Will Register and Make the New Lower-Strength lopinavir/ritonavir Tablet Available in More Than 150 Countries to Support Broad Access for the More Than 2 Million Children Living with HIV Worldwide
Abbott today announced that it has received U.S. Food and Drug Administration (FDA) approval for a new lower-strength tablet formulation of its leading HIV protease inhibitor, Kaletra® (lopinavir/ritonavir), which is also marketed as Aluvia® (lopinavir/ritonavir) in developing countries. The lower-strength Kaletra tablets will be available in the U.S. this month.
Abbott is awaiting EMEA marketing authorization for the Kaletra/Aluvia lower-strength tablets. Upon EMEA marketing authorization, Abbott intends to register this new tablet formulation in more than 150 countries. The soft gel capsule formulation of LPV/r is the most widely registered protease inhibitor in the world. The original tablet formulation is already available in 93 countries and Abbott is awaiting approval in an additional 45 countries for this formulation.
Approval of this lower-strength Kaletra tablet represents an important step in Abbott’s ongoing commitment to the global fight against HIV because:
* The tablets do not require refrigeration and can be taken with or without a meal – an important advance in delivering HIV medicine to children in developing countries.
* The World Health Organization (WHO) estimates 2 million children were living with HIV/AIDS in sub-Saharan Africa at the end of 2006.
* The new lower-strength tablets are smaller in size than original Kaletra tablets and contain the same proven active ingredients as Abbott’s Kaletra oral solution. The lower-strength Kaletra tablet is approved for children weighing 15kg or more who are able to swallow the intact tablet.
* The FDA approval expands available options for using the first and only co-formulated protease inhibitor tablet to treat children with HIV.
“HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world,” said Scott Brun, M.D., divisional vice president, infectious diseases and renal development, Global Pharmaceutical Research and Development, Abbott. “Abbott developed a lower-strength tablet formulation of Kaletra to give physicians an innovative treatment option to help curb the impact of HIV infection in children.”
The price of the recently approved lower-strength tablet will be half the price of the original tablet in the developing world.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.